# BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

> **NCT07625644** · PHASE3 · RECRUITING · sponsor: **SystImmune Inc.** · enrollment: 550 (estimated)

## Conditions studied

- Small Cell Lung Cancer Extensive Stage
- Small-cell Lung Cancer
- Small Cell Carcinoma
- Sclc
- SCLC,Extensive Stage
- Lung Cancer
- Lung Cancer Metastatic
- Lung Cancer Stage IV

## Interventions

- **DRUG:** BL-M14D1 and Atezolizumab
- **DRUG:** Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin

## Key facts

- **NCT ID:** NCT07625644
- **Lead sponsor:** SystImmune Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-04
- **Primary completion:** 2030-01
- **Final completion:** 2031-06
- **Target enrollment:** 550 (ESTIMATED)
- **Last updated:** 2026-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07625644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07625644, "BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07625644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*